NTRK1 and lung cancer: This study reported 1 patient with glioneuronal tumor and BCAN-NTRK1 fusion and 1 patient with brain metastases from lung cancer and SQSTM1-NTRK1 fusion, and both patients showed an evaluable response to entrectinib, which supports the CNS activity of entrectinib (45).